by What Are Biosimilars? A Simple, Patient-Friendly Guide
16 Mar, 2026When you hear the word biosimilars, it might sound confusing - like a mix of science and jargon. But here’s the simple truth: biosimilars are not new or experimental. They’re proven, safe, and often more affordable versions of powerful biologic drugs you may already know.
What’s the Difference Between Biosimilars and Generics?
Most people know generics - like the generic version of ibuprofen or metformin. These are exact chemical copies of older, small-molecule drugs. They’re made in a lab using precise formulas, so every pill is nearly identical to the brand-name version.
Biosimilars? They’re not like that.
Biologic drugs - the ones biosimilars copy - are made from living things: human or animal cells, bacteria, or yeast. Think of them like a complex recipe made in a living kitchen. Even tiny changes in temperature, ingredients, or process can change the final product. That’s why a biosimilar can’t be an exact copy. It’s designed to be highly similar - with no meaningful difference in how it works, how safe it is, or what side effects it causes.
The FDA says it plainly: biosimilars must match the original biologic in safety, purity, and strength. That’s not a guess. It’s backed by years of lab tests, animal studies, and real patient trials.
How Are Biosimilars Made - And Why Does It Matter?
Biologics are made from living cells that have been genetically modified to produce specific proteins - like antibodies that target inflammation or cancer cells. These proteins are huge, complex molecules, often with sugars attached. The exact shape, folding, and structure of these molecules determine how well they work in your body.
Manufacturing a biosimilar means starting with a similar living cell line, using similar processes, and testing every step to prove it behaves just like the original. It’s not just about the final product. It’s about how it’s made - from the cell culture to the final injection.
That’s why biosimilars cost more to develop than generics. A generic drug might cost $1 million to bring to market. A biosimilar? Often over $100 million. But the payoff? Lower prices for patients.
Are Biosimilars Safe? Real Evidence, Real Results
Some patients worry: “If it’s not the same, is it safe?”
Here’s what the data says: since the first biosimilar was approved in the U.S. in 2015 (Zarxio, for chemotherapy patients), over 30 biosimilars have been approved and used by hundreds of thousands of people. In Europe, where biosimilars have been around since 2006, studies show no increase in side effects or loss of effectiveness compared to the original biologics.
Take Renflexis, a biosimilar for rheumatoid arthritis. Before approval, it was tested in 541 patients - and matched the original drug exactly in how well it reduced joint pain and swelling. Same dose. Same frequency. Same results.
The FDA doesn’t approve biosimilars unless they meet the same strict manufacturing standards as the original. And once approved, every biosimilar is tracked. If someone has a reaction, it’s reported, studied, and acted on - just like the original drug.
What Conditions Are Treated With Biosimilars?
Biosimilars aren’t just for one disease. They’re used to treat serious, long-term conditions where biologics have changed lives:
- Autoimmune diseases like rheumatoid arthritis, psoriasis, and Crohn’s disease
- Cancer - especially breast cancer, colon cancer, and lymphoma
- Diabetes - biosimilar insulins help control blood sugar
- Chronic kidney disease
- Macular degeneration (a leading cause of vision loss)
For example, biosimilars for adalimumab (Humira) and infliximab (Remicade) are now widely used to treat inflammatory conditions. These drugs used to cost over $2,000 per dose. Biosimilars can cut that cost by 20-30% - and sometimes even more.
How Do You Know If You’re Getting a Biosimilar?
Biosimilars have names that look similar - but not identical - to the original.
Take infliximab - the original drug. Its biosimilar might be called infliximab-dyyb. The extra four letters at the end are not random. They’re a unique identifier, like a fingerprint, so doctors and pharmacists can track exactly which version you’re taking.
Your doctor will tell you if you’re being prescribed a biosimilar. Your insurance might also push you toward one because it’s cheaper - and that’s okay. Switching from the original biologic to a biosimilar has been studied extensively. Multiple trials show it’s safe and effective. You won’t lose effectiveness. You won’t suddenly have new side effects.
Cost Matters - Here’s What You Can Expect
Biologics are among the most expensive drugs in the world. A single dose of Humira can cost over $2,500. Without insurance, that’s $30,000 a year.
Biosimilars don’t always cut the price in half - but they do cut it significantly. Most cost 15-30% less. In some cases, when multiple biosimilars enter the market, prices drop even further. One study estimated that biosimilars could save the U.S. healthcare system over $54 billion between 2017 and 2026.
For patients, that means lower copays. Fewer refusals from insurance. More people getting the treatment they need.
What About “Interchangeable” Biosimilars?
There’s a special category called “interchangeable” biosimilars. These are biosimilars that the FDA says can be swapped for the original drug without the doctor’s approval - just like a generic.
The first one approved was Semglee, an insulin glargine biosimilar for diabetes. It’s now being used by many patients who need daily insulin. This is a big step forward - it means easier access and fewer barriers.
More interchangeable biosimilars are coming. The FDA is speeding up approvals to make sure patients get these savings as quickly as possible.
What Should You Do If Your Doctor Suggests a Biosimilar?
Ask questions. But don’t assume it’s a downgrade.
Here’s what to ask:
- Is this a biosimilar? If so, which one?
- Has it been tested in people like me?
- Will it work the same way as the original?
- Will my insurance cover it?
- What happens if I switch from the original?
Most patients who switch report no change in how they feel. No new side effects. No drop in effectiveness. In fact, many feel better because they’re finally able to afford their treatment.
Never stop or switch without talking to your doctor. But if your doctor says it’s a good option - trust the science. Biosimilars aren’t a compromise. They’re a smart, safe, and proven choice.
Final Thought: You’re Not Getting Second-Best
Biosimilars aren’t “cheap knockoffs.” They’re carefully built, rigorously tested, and medically identical in every way that matters.
They exist because biologics saved lives - but were too expensive for too many people. Biosimilars are the answer: bringing the same power, the same safety, and the same hope - at a price more people can afford.
If you’re on a biologic today - or thinking about starting one - ask your doctor: Is there a biosimilar option for me? You might be surprised by how much it could change your life.
Are biosimilars the same as generics?
No. Generics are exact chemical copies of small-molecule drugs - like aspirin or metformin. Biosimilars are highly similar to complex biologic drugs made from living cells. They can’t be exact copies because biologics are too complex. But they must prove they work the same way, with the same safety and effectiveness.
Are biosimilars safe?
Yes. The FDA requires extensive testing - including lab studies, animal tests, and clinical trials - before approving any biosimilar. Over 30 have been approved in the U.S., and millions of patients have used them. Studies in Europe, where they’ve been used for over 15 years, show no increase in side effects or loss of effectiveness.
Can I switch from a biologic to a biosimilar?
Yes. Multiple studies show that switching from a reference biologic to a biosimilar is safe and effective. Your body won’t react differently. Your condition won’t worsen. Many patients switch without even noticing a difference. Always talk to your doctor before switching, but there’s no reason to fear it.
Why are biosimilars cheaper than the original biologics?
Because they don’t need to repeat all the early research. The original biologic already proved it works. Biosimilar makers only need to prove their version is highly similar - which is expensive, but far less than developing a new drug from scratch. That savings gets passed on to patients and insurers.
Will my insurance require me to use a biosimilar?
Sometimes. Many insurance plans encourage or require biosimilars because they’re less expensive. This is called “step therapy.” If your plan does this, it’s legal and common. You can still ask your doctor if the original is medically necessary - but in most cases, biosimilars work just as well.
How do I know if I’m getting a biosimilar?
The name will be slightly different. For example, if your drug is infliximab, the biosimilar might be infliximab-dyyb. The four-letter ending is a unique identifier. Your doctor or pharmacist will tell you if you’re getting a biosimilar. You can also check your prescription label or ask your pharmacy.
Do biosimilars have the same side effects as the original?
Yes. Since biosimilars are designed to be highly similar, their side effect profiles are nearly identical. Clinical trials are specifically designed to detect any differences in safety. If a biosimilar had new or worse side effects, it wouldn’t be approved.
Are biosimilars used for cancer treatment?
Yes. Several biosimilars are approved for cancer, including versions of trastuzumab (Herceptin) for breast cancer, bevacizumab (Avastin) for colon cancer, and rituximab (Rituxan) for lymphoma. These biosimilars have been studied in thousands of cancer patients and are now standard options in oncology.
What’s the difference between a biosimilar and a bioidentical?
A bioidentical is made using the exact same production process as the original biologic - meaning it’s chemically identical. Biosimilars are made with a similar process and must be highly similar, but not identical. Bioidenticals are rare. Most approved products are biosimilars, not bioidenticals.
Is there a biosimilar for insulin?
Yes. Semglee is an interchangeable biosimilar to insulin glargine (Lantus). It’s been approved since 2021 and is now widely used. Other insulin biosimilars are also in development. These are helping people with diabetes save hundreds - even thousands - of dollars a year.